Genialis, a leader in applied data science for the development of precision medicines, today announced a collaborative partnership with OncXerna, an international, clinical-stage biopharma developing next-generation immunotherapies for cancer. Early work between the two companies has thus far focused on modeling gene expression signatures predictive of treatment for gastric cancer. The patent-pending enhanced methodology will further OncXerna’s clinical development plans to expand beyond gastric cancer to other tumor microenvironment phenotypes.

Read the press release in its entirety here.